Sellas Life Sciences Group Inc (SLS) - News Archive

Showing 5 of 25 results.

Revolutionary Immunotherapy Combo Uplifts Survival Prospects for Advanced Malignant Pleural Mesothelioma Patients

Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the lining of the lungs and is primarily caused by exposure to asbestos. It has a poor prognosis, with limited treatment options and a median sur...

Dec 27, 2023 Clinical Study

Sellas' Groundbreaking Drug SLS009 Grabs FDA's Attention with Orphan Drug Designation, Offering Hope for Peripheral T-cell Lymphoma Patients

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasSellas Life Sciences Group, Inc. (Sellas), a clinical-stage biopharmaceutical company focused on developing innovative i...

Dec 21, 2023 • Major Pharmaceutical Preparations Industry Product Service News

SELLAS Life Sciences Aims Higher: Promising Advancements in Clinical Trial of SLS009 for Acute Myeloid Leukemia Offer New Hope

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort, Advancement in Clinical Trial of SLS009 in Acute Myeloid LeukemiaSELLAS Life Sciences recently announced a significant milestone in their ongo...

Dec 14, 2023 • Major Pharmaceutical Preparations Industry Clinical Study

SELLAS Life Sciences, a biopharmaceutical company focused on developing novel cancer immunotherapies, has recently received a positive recommendation from the REGAL Independent Data Monitoring Committee (IDMC) for their investigational drug, Galinpepimut-S, in the treatment of Acute Myeloid Leukemia (AML) The IDMC recommended the continuation of the Phase 3 REGAL trial without any modifications, marking a significant milestone in the development of this potential treatment option for AML patients

Dec 4, 2023 Clinical Study

SELLAS Life Sciences Makes Strides Towards Groundbreaking AML Treatment as Target Enrollment Reached in Galinpepimut-S Phase 3 REGAL Trial: Independent Data Monitoring Committee to Convene This Quarter

SELLAS Life Sciences, a leading global biopharmaceutical company, recently announced that it has successfully reached its target enrollment for the Phase 3 REGAL trial of Galinpepimut-S in patients with Acute Myeloid Le...

Nov 29, 2023 Clinical Study